

FDA recalls heart medication valsartan, citing cancer concerns

17 July 2018, by Monique O. Madan, Miami Herald

The U.S. Food and Drug Administration issued a voluntary recall of several medications that contain the active ingredient valsartan, which is used to treat high blood pressure and heart failure.

"This recall is due to an impurity, N-nitrosodimethylamine (NDMA), which was found in the recalled products, the FDA said in a statement. "However, not all products containing valsartan are being recalled."

Officials say NDMA is classified as a probable human carcinogen—a substance that could cause cancer. They said that finding findings are based on results from recent laboratory tests.

The FDA said the carcinogen's presence is "thought to be related to changes in the way the active substance was manufactured."

"We have carefully assessed the valsartan-containing medications sold in the United States, and we've found that the valsartan sold by these specific companies does not meet our safety standards. This is why we've asked these companies to take immediate action to protect patients," said Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research.

Patients already taking the recalled medications should contact their pharmacist or doctor immediately, the FDA says.

To determine whether a specific product has been recalled, patients should look at the drug name and [company](#) name on the label of their prescription bottle. If the information is not on the bottle, [patients](#) should contact the pharmacy that dispensed the medicine.

The specific medicines recalled are:

- Valsartan, Major Pharmaceuticals.
- Valsartan, Solco Healthcare.

- Valsartan, Teva Pharmaceuticals Industries Ltd.
- Valsartan/Hydrochlorothiazide (HCTZ), Solco Healthcare.
- Valsartan/Hydrochlorothiazide (HCTZ), Teva Pharmaceuticals Industries Ltd.

©2018 Miami Herald

Distributed by Tribune Content Agency, LLC.

APA citation: FDA recalls heart medication valsartan, citing cancer concerns (2018, July 17) retrieved 7 July 2022 from <https://medicalxpress.com/news/2018-07-fda-recalls-heart-medication-valsartan.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.